文献速递肝病消化道肿瘤与早癌

肝细胞癌患者的精神障碍:美国大型商业保险人群队列研究

Psychiatric disorders in patients with hepatocellular carcinoma: A large US cohort of commercially insured individuals.
PubMed 文献 · Aliment Pharmacol Ther · 2024-06-11

基于美国商业保险理赔数据库,纳入11609例新诊断肝细胞癌患者,2166例(18.6%)在癌症诊断后出现精神障碍诊断,最常见为抑郁(58.3%)和焦虑(53.0%)。女性、既存精神障碍诊断及肝癌治疗类型与精神障碍诊断显著相关,精神障碍诊断比例从2006-2009年的14.8%升至2018-2021年的21.1%(p < 0.001)。

要点

  • 新诊断肝细胞癌患者中18.6%在癌症诊断后出现精神障碍诊断,抑郁和焦虑最常见。
  • 女性、既存精神障碍诊断及移植、局部治疗、临终关怀等治疗类型与精神障碍诊断显著相关。
  • 精神障碍诊断比例从2006-2009年14.8%升至2018-2021年21.1%(p < 0.001)。

核心结论

  • 近2/10的肝细胞癌患者在癌症诊断后被诊断精神障碍,并识别出独特的社会人口学和临床危险因素。
  • 这突出表明新诊断肝细胞癌患者心理负担增加的风险,需要早期评估和治疗。

研究设计与样本

  • 使用IQVIA PharMetrics® Plus for Academics全国代表性商业保险理赔数据库,识别新诊断肝细胞癌患者的精神障碍诊断和治疗。
  • 采用多变量逻辑回归模型识别与精神障碍诊断和治疗相关的因素。
  • 共纳入11609例新诊断肝细胞癌患者。

主要发现

  • 2166例(18.6%)患者在癌症诊断后出现精神障碍诊断,其中抑郁占58.3%、焦虑占53.0%。
  • 女性(aOR 1.33,95% CI [1.19-1.49])、既存精神障碍诊断(aOR 9.12 [8.08-10.3])及肝细胞癌治疗类型(移植:aOR 2.15 [1.66-2.77];局部治疗:aOR 1.74 [1.52-1.99];临终关怀:aOR 2.43 [1.79-3.29])与精神障碍诊断显著相关。
  • 女性、腹水、较高合并症负担及治疗类型与新发精神障碍诊断相关。
  • 有精神障碍诊断的患者中1392例(64.3%)接受药物治疗,最常用为抗抑郁药(46.2%)和抗焦虑药(32.8%)。
  • 精神障碍诊断比例从2006-2009年的14.8%升至2018-2021年的21.1%(p < 0.001)。

临床怎么用

  • 原文结论指出新诊断肝细胞癌患者心理负担增加的风险,需要早期评估和治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND/AIMS: Patients with hepatocellular cancer (HCC) are vulnerable to psychological distress given a new cancer diagnosis superimposed on pre-existing chronic liver disease. We aimed to characterise the psychiatric burden in HCC, risk factors for incident diagnosis and treatment patterns over time. METHODS: Using IQVIA PharMetrics® Plus for Academics-a nationally representative claims database of the commercially insured US population-we identified psychiatric diagnoses and treatment among patients with newly diagnosed HCC. Multivariable logistic regression modelling identified factors associated with psychiatric diagnosis and treatment. RESULTS: Of 11,609 patients with HCC, 2166 (18.6%) had a psychiatric diagnosis after cancer diagnosis with depression (58.3%) and anxiety (53.0%) being most common. Women (aOR 1.33, 95% CI [1.19-1.49]), pre-existing psychiatric diagnoses (aOR 9.12 [8.08-10.3]) and HCC treatment type (transplant: aOR 2.15 [1.66-2.77]; locoregional therapies: aOR 1.74 [1.52-1.99]; hospice: aOR 2.43 [1.79-3.29]) were significantly associated with psychiatric diagnosis. Female sex, ascites, higher comorbidity and treatment type were associated with incident psychiatric diagnosis. Pharmacotherapy was used in 1392 (64.3%) patients with a psychiatric diagnosis, with antidepressants (46.2%) and anxiolytics (32.8%) being most common. Psychiatric diagnoses increased from 14.8% in 2006-2009 to 21.1% in 2018-2021 (p < 0.001). In almost 20% of patients with pre-existing psychiatric conditions, therapy was discontinued after HCC diagnosis. CONCLUSIONS: Nearly 2 of 10 patients with HCC were diagnosed with a psychiatric condition after cancer diagnosis with unique sociodemographic and clinical risk factors identified. This highlights a risk for increased psychological burden in need of early evaluation and treatment among patients with newly diagnosed HCC.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Patel MJ, Jones A, Jiang Y, et al. Psychiatric disorders in patients with hepatocellular carcinoma: A large US cohort of commercially insured individuals. Aliment Pharmacol Ther. 2024. PMID: 38863242. doi:10.1111/apt.18115

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。